Misplaced Pages

Revision as of 23:50, 1 October 2023

This page is not a forum for general discussion about Finasteride. Any such comments may be removed or refactored. Please limit discussion to improvement of this article. You may wish to ask factual questions about Finasteride at the Reference desk.

This is the talk page for discussing improvements to the Finasteride article. This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic. New to Misplaced Pages? Welcome! Learn to edit; get help. Assume good faith Be polite and avoid personal attacks Be welcoming to newcomers Seek dispute resolution if needed Article policies Neutral point of view No original research Verifiability

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: Index, 1, 2, 3, 4, 5, 6, 7, 8Auto-archiving period: 3 months

Ideal sources for Misplaced Pages's health content are defined in the guideline Misplaced Pages:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Finasteride. PubMed provides review articles from the past five years (limit to free review articles) The TRIP database provides clinical publications about evidence-based medicine. Other potential sources include: Centre for Reviews and Dissemination and CDC

This article has not yet been rated on Misplaced Pages's content assessment scale. It is of interest to the following WikiProjects:

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details. Pharmacology Mid‑importance This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology Mid This article has been rated as Mid-importance on the project's importance scale. Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details. Chemicals Mid‑importance This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Misplaced Pages's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals Mid This article has been rated as Mid-importance on the project's importance scale. Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details. Medicine Mid‑importance This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Misplaced Pages talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine Mid This article has been rated as Mid-importance on the project's importance scale. Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details. Women's Health Mid‑importance This article is within the scope of WikiProject Women's Health, a collaborative effort to improve the coverage of Women's Health on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Women's HealthWikipedia:WikiProject Women's HealthTemplate:WikiProject Women's Healthwomen's health Mid This article has been rated as Mid-importance on the importance scale.

The following Misplaced Pages contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view. Doors22 (talk · contribs) This user has contributed to the article.

Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Misplaced Pages:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent.

Post finasteride syndrome

I strongly feel like this section is outdated and uses low quality evidence.

Since this year there are diagnostic criteria for PFS published in "International Journal of Risk & Safety in Medicine" https://content.iospress.com/articles/international-journal-of-risk-and-safety-in-medicine/jrs210023. This should be mentioned along with an outline of those criteria.

Other than that there are at least two papers that discuss a possible epigenetic pathomenachism:

"Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652249/ Conclusion: "For the first time, we demonstrate a tissue-specific methylation pattern of SRD5A2 promoter in PFS patients. Although we cannot conclude whether this pattern is prenatally established or induced by finasteride treatment, it could represent an important mechanism of neuroactive steroid levels and behavioural disturbances previously described in PFS."

Epigenetic Effects of Finasteride on Human Leydig Cells https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.2020.34.s1.03823

This should at least be mentioned.

Other than that there is one part in the current article that needs to be removed: "It has common features with other self-diagnosed "mystery syndromes" such as morgellons syndrome or multiple chemical sensitivity."

1. It is quoted incorrectly. In the cited source you cannot find this quote word by word. This is where it was taken from, but it is edited: "In our opinion, PFS demonstrates some analogies to such controversial “mystery syndromes” as amalgam illness, multiple chemical sensitivity, Morgellons disease, and Koro for the following reasons: patients complain of symptoms that cannot be adequately explained biologically, and the frequency of consultations for the conditions parallels the respective media coverage, which points to a high degree of suggestibility."

2. As it is made clear in the source this is a personal opinion of the authors.

3. There is no evidence in the source to back up this opinion.

4. The only reason given for that opinion is the reason that there is no known biological explanation. Jumping from the lack of knowledge to a conclusion is a mockery of evidenced based medicine. Moreover there are attempts to explain the syndrome (see epigenetic changes I mentioned before).

5. The source is low quality "evidence" at best. It is a single case report (https://en.wikipedia.org/Wikipedia:Identifying_reliable_sources_(medicine)) about a patient of the authors, which they use as the basis for really bold claims that are entirely unsupported.

Franzpuntila (talk) 17:45, 28 November 2021 (UTC)

"Finasteride" is repeated many times in the Pharmacokinetics section.

Try reading this out loud, it doesn't really flow. Not sure how to improve it while staying clear though..

At steady-state with 1 mg/day finasteride, mean peak concentrations of finasteride were 9.2 ng/mL (25 nmol/L). Conversely, following a single 5 mg dose of finasteride, mean peak levels of finasteride were 37 ng/mL (99 nmol/L),

Ckiedits (talk) 15:55, 20 March 2022 (UTC)

Extended-confirmed-protected edit request on 21 March 2022

This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.

In the Adverse Effects section the comment on contraindication in pregnancy should be improved. The current text is:

Finasteride is contraindicated in pregnancy. The Food and Drug Administration advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride.

I suggest, based on Refs 36 and 37, that the above be altered to:

Finasteride is contraindicated for women who are pregnant or become pregnant while exposed to it, as it may cause abnormalities in a male fetus. Exposure through skin contact to broken or crushed tablets is identified by as a risk vector. The Food and Drug Administration advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride.

The motivation for this edit is to clarify the information on a serious risk and when it applies. Silverfoil92 (talk) 04:50, 21 March 2022 (UTC)

Removing a floating 'by' from the suggested text.

Finasteride is contraindicated for women who are pregnant or become pregnant while exposed to it, as it may cause abnormalities in a male fetus. Exposure through skin contact to broken or crushed tablets is identified as a risk vector. The Food and Drug Administration advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride. Silverfoil92 (talk) 04:52, 21 March 2022 (UTC)

 Not done for now: please establish a consensus for this alteration before using the {{edit extended-protected}} template. Dr.Pinsky (talk) 18:24, 26 March 2022 (UTC)

Adverse Effects section - exposure and pregnancy

I wish to propose an addition to the Adverse Effects section. For the comment on contraindication in pregnancy I think it could be improved. The current text is:

Finasteride is contraindicated in pregnancy. The Food and Drug Administration advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride.

I suggest, based on Refs 36 and 37 (manufacturers' prescribing information as deposited with the FDA), that the above be altered to:

Finasteride is contraindicated for women who are pregnant or become pregnant while exposed to it, as it may cause abnormalities in a male fetus. Exposure through skin contact to broken or crushed tablets is identified as a risk vector. The Food and Drug Administration advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride.

The motivation for this proposed edit is to (i) specify the reason as to why finasteride is contraindicated (abnormalities in the male fetus may be caused) and (ii) to add a comment that skin contact is a risk vector. I think that the latter is important to include as this is important information for someone who may have come into contact with finasteride unwantedly due to the serious consequences.

Silverfoil92 (talk) 13:56, 31 March 2022 (UTC)

Separate article for post-finasteride syndrome

Hi all,

I recently drafted an article for post-finasteride syndrome, which I hope addresses some of the concerns raised about the original version of the article (search Draft:post-finasteride syndrome to view the article). After submitting for review, I was notified that I should start a discussion here to seek consensus as to whether the topic merits its own article, as opposed to a sub-section of the finasteride article. I personally believe PFS should be covered in its own article, in order to address the reporting, research, and controversy surrounding the topic in sufficient depth.

Does anyone have any thoughts on this action, or suggestions for improving the draft as it currently stands?

Best,

Xardwen (talk) 20:04, 28 June 2023 (UTC)

There is currently a locked redirect at Post-finasteride syndrome, following disruptive editing, largely by IPs, in April 2021. Because the title is protected, a reviewer can't accept Draft:Post-finasteride syndrome. If a reviewer wants to accept Draft:Post-finasteride syndrome, they will first have to find an administrator to unlock the title, and I wouldn't expect an administrator to unlock the title without seeing a consensus in favor of creating an article. Robert McClenon (talk) 05:42, 29 June 2023 (UTC)

Sounds good, thanks for the note- in the event that no other editors feel compelled to comment and establish a consensus, is there another place where I should go to raise this issue?

Best,Xardwen (talk) 05:53, 3 July 2023 (UTC)

Recent developments & sources

Editors may want to consider the following for the article.

Regulatory news

1. Boxed warnings were added to finasteride (1 mg) packaging per ANSM

France's national regulator ANSM required all manufacturers add a red boxed warning to all finasteride 1 mg boxes on sexual and psychiatric adverse effects. Organon, the current marketing authorization holder, removed the drug from the market in France.

Source: Finastéride 1 mg (Propecia et génériques) : ajout de mentions d’alerte sur les boîtes pour renforcer l’information sur les effets indésirables. ANSM (France). November 30, 2022.

2. FDA required new disclosure of risk of suicidal ideation and behavior to finasteride (1 mg) label

Source: Levine, Dan. FDA requires disclosure of suicide risk for anti-baldness drug. Reuters. June 10, 2022.

3. Health Canada alerting doctors to risk of suicidal ideation and self-injury

Health Canada Safety Review, Jan 19 2023

From key points: “Health Canada's review of the available information found a possible link between the use of finasteride and the risks of suicidal ideation and self-injury..." The agency will update product information and inform healthcare professionals through a regulatory communication.

4. UK Medicines and Healthcare products Regulatory Agency (MHRA) launches a safety review of finasteride

Source: Ennals, Ethan. “Watchdog launches investigation into hair loss pill...” Daily Mail. March 4, 2023.

Medical literature

New review: Leliefeld HHJ, Debruyne FMJ & Reisman Y. The post-finasteride syndrome: possible etiological mechanisms and symptoms. Int J Impot Res. 2023. doi:10.1038/s41443-023-00759-5

A statement of limitations is relevant: "LIMITATIONS. Scientific literature on the PFS has the intrinsic limitation, by definition, that symptoms can persist or even appear after cessation of the 5ARIs and therefore have been unnoticed and not documented in the literature. The earlier mentioned lack of quality studies has hampered our knowledge of the presence, frequency and duration of the side effects...” Mariedegournay (talk) 23:44, 1 October 2023 (UTC)

• All unassessed articles
• B-Class pharmacology articles
• Mid-importance pharmacology articles
• WikiProject Pharmacology articles
• B-Class chemicals articles
• Mid-importance chemicals articles
• B-Class medicine articles
• Mid-importance medicine articles
• All WikiProject Medicine pages
• B-Class women's health articles
• Mid-importance women's health articles
• WikiProject Women's Health articles
• Articles edited by connected contributors